Glenmark Q3 net profit rises 64% to Rs 190.83 cr; to raise $400 mn
The company had posted a net profit of Rs 116.34 crore in the corresponding period of the previous financial year, Glenmark Pharmaceuticals said in a filing to the BSE.14-02-2020
14-02-2020
Glenmark Pharmaceuticals Ltd - 532296 - Unaudited Financial Results For The Quarter And Nine Months Ended December 31, 2019
The Board of Directors of Glenmark Pharmaceuticals Limited at its meeting held on February 14, 2020, which commenced at 02.00 p.m. and concluded at 6.40 p.m., considered and approved the following: 1. Pursuant to Regulations 30 and 33 of the SEBI LODR, 2015, we wish to inform you that Board has today at its meeting approved the Unaudited Financial Results for the Third Quarter and Nine Months ended December 31, 2019. The copy of the said results together with Management Discussion & Analysis, Press Release and Limited Review Report of the Auditors is enclosed herewith. These are also being made available on the website of the Company at www.glenmarkpharma.com.14-02-2020
Glenmark board to consider fund raising options on February 14
The Mumbai-based firm plans to raise funds either through issuance of bonds or debentures, non-convertible debt instruments or any other securities or any combination thereof, of any of the above, it added.11-02-2020
Glenmark Pharmaceuticals Ltd - 532296 - Update on board meeting
The Board Meeting to be held on 14/02/2020 has been revised to 14/02/2020 We have to inform you that the Board of Directors of the Company, at its meeting scheduled on February 14, 2020, will, inter-alia, consider and evaluate proposals for raising of funds either by issuance of bonds / debentures / non-convertible debt instruments or any other securities or any combination thereof, of any of the above, for refinancing of bonds/FCCBs/loans, in accordance with the FEMA ECB Guidelines, and other applicable regulations, guidelines and laws of India, and subject to all necessary regulatory, statutory and shareholder approvals, as may be required.11-02-2020
D-Street Buzz: Pharma stocks gain led by Glenmark; volumes of Taj GVK, Parag Milk spike
India VIX shed 2.53 percent and was trading at 13.85 level.11-02-2020
GLENMARK PHARMACEUTICALS LTD. - 532296 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Enclosed please find herewith the details of Earnings Call slated for Monday, February 17, 2020 at 8:30 a.m. - 9:30 a.m. (IST), for your information and record. Please note that the recording of the call will be available on our website within 24 hours of the call.04-02-2020
GLENMARK PHARMACEUTICALS LTD. - 532296 - Closure of Trading Window
We have to inform you that, pursuant to Regulation 29 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, a meeting of the Board of Directors will be held on Friday, February 14, 2020, inter alia, to consider and approve the Unaudited Financial Results of the Company for the Third Quarter and Nine Months ended December 31, 2019. Further, as per the "Code of Conduct for Prevention of Insider Trading" and pursuant to the SEBI (Prohibition of Insider Trading) Regulations, 2015 the Company has intimated its Directors and other designated persons regarding the closure of trading window from December 31, 2019 to February 16, 2020 (both days inclusive) for the purpose of approval of Unaudited Financial Results for the Third Quarter and Nine Months ended December 31, 2019.31-01-2020
GLENMARK PHARMACEUTICALS LTD. - 532296 - Board Meeting Intimation for Board Meeting Intimation For Considering And Approving Unaudited Financial Results Of The Company For The Third Quarter And Nine Months Ended December 31, 2019.
GLENMARK PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/02/2020 ,inter alia, to consider and approve We have to inform you that, pursuant to Regulation 29 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, a meeting of the Board of Directors will be held on Friday, February 14, 2020, inter alia, to consider and approve the Unaudited Financial Results of the Company for the Third Quarter and Nine Months ended December 31, 2019. Further, as per the "Code of Conduct for Prevention of Insider Trading" and pursuant to the SEBI (Prohibition of Insider Trading) Regulations, 2015 the Company has intimated its Directors and other designated persons regarding the closure of trading window from December 31, 2019 to February 16, 2020 (both days inclusive) for the purpose of approval of Unaudited Financial Results for the Third Quarter and Nine Months ended December 31, 2019.31-01-2020
Glenmark Pharma sells gynaecology business, share price gains
The share touched its 52-week high Rs 668.25 and 52-week low Rs 267.30 on 16 January, 2019 and 14 November, 2019, respectively.22-01-2020
GLENMARK PHARMACEUTICALS LTD. - 532296 - Announcement under Regulation 30 (LODR)-Meeting Updates
Disclosure under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 201521-01-2020